Efficacy of open-label nefazodone treatment in patients with panic disorder.
Fifteen patients with panic disorder participated in a 12-week treatment trial with open-label nefazodone. Nefazodone was well-tolerated with minimal side effects; none of the patients reported sexual dysfunction, and only one patient experienced weight gain. Although the response rate was lower than that found with most other antipanic medications, given its favorable side effect profile, nefazodone may be a good alternative for patients apprehensive about potential adverse drug reactions.
Papp
L A
LA
Department of Clinical Psychobiology, New York State Psychiatric Institute, New York 10032,USA. lap2@columbia.edu
Coplan
J D
JD
Martinez
J M
JM
de Jesus
M
M
Gorman
J M
JM
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D010879:Piperazines; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone